|
|
|
|
Office Locations:
|
4203 Montrose Blvd., Suite 250
Houston, TX 77006
Phone: 512-721-1200
| |
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
Founded in 2006, Sante Ventures invests primarily in seed and early-stage companies developing innovative new medical technologies and healthcare services. The firm has $260 million under management across two funds. Sante Ventures invests nationally with a focus on the Central U.S., and has offices in Austin, Houston and Boston. The firm maintains a close working relationship with Austin Ventures. Sante generally invests $2-6 million per round and targets $4-12 million in total capital invested over the life of a company, but is flexible based on the needs of the company.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
|
| Name | |
| |
Title | |
Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
|
| Brett Skukauski | |
CPA | |
Controller | |
| Brooke Jones | |
| |
Head of Capital Formation | |
| Casey Cunningham | |
MD | |
Chief Scientific Officer | |
| David Kaufman | |
| |
Chief Operating Office | |
| Douglas D. French | |
| |
Founding Managing Director | |
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
04/15/2026
|
Sonire Therapeutics
|
CA
|
$18,000,000
|
Series A
|
04/13/2026
|
Endovascular Engineering
|
CA
|
$80,000,000
|
Series C
|
02/05/2026
|
beHuman
|
FL
|
$4,000,000
|
Seed
|
11/19/2025
|
AI Proteins
|
MA
|
$41,500,000
|
Series A
|
09/26/2025
|
Axon Therapies
|
NY
|
$32,000,000
|
Series A
|
08/18/2025
|
Reprieve Cardiovascular
|
MA
|
$61,000,000
|
Series B
|
|
|
|
|
|
|
|
